Aptevo Therapeutics Inc..
APVO.US | Research and experimental development on natural sciences and engineering
Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. Their primary focus is on leveraging their proprietary ADAPTIR modular protein technology platform to create bispecific and multi-specific antibodies. These antibodies ...Show More
Better Health for All
-30
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company entirely devoted to developing novel immunotherapies for cancer and autoimmune diseases, with a mission to enhance lives. Its product portfolio, including two clinical and six preclinical candidates, is focused on health improvement, with no evidence of products having negative health outcomes.
1
Mipletamig, a key candidate for Acute Myeloid Leukemia (AML), has shown a 93% overall response rate and 73% complete remission rate in evaluable patients.
2
However, APVO436 had a less than 30% incidence of Cytokine Release Syndrome (CRS) across all trial cohorts, with the majority being grades 1 & 2.
3
The IXINITY Savings Program offers up to $12,000 annually but requires commercial insurance, while the Patient Assistance Program helps uninsured patients.
4
Mipletamig received orphan drug designation for AML, and the RAINIER study includes adults aged 18 or older who are unfit for intensive chemotherapy, with a median patient age of 75.
5
The company's R&D expenses were $17.1 million in 2023.
6
Aptevo is committed to providing an environmentally safe workplace and requires safeguarding company information and data, with a privacy policy effective December 24, 2018.
7
The company conducts multi-center clinical trials and collects demographic and medical information for eligibility, obtaining consent when required by law.
8
Fair Money & Economic Opportunity
0
Aptevo Therapeutics Inc. is a biotechnology company focused on developing immunotherapies, not a financial institution.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, the company does not offer consumer credit products, financial services, or manage customer financial data relevant to the KPIs. While Aptevo and its partners offer patient assistance programs that provide co-pay assistance up to $12,000 annually and free trial programs for uninsured or underinsured individuals,
2
the provided articles do not contain quantitative data on the percentage of its total patient base that are underserved or benefit from these programs, nor do they provide information on APRs, fee structures, or loan books. The company's financial activities, such as debt repayment and equity offerings, relate to corporate finance, not consumer financial services.
3
Fair Pay & Worker Respect
0
No evidence available to assess Aptevo Therapeutics Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The documents discuss the company's internal Code of Conduct and Business Ethics, employee diversity, and general regulatory compliance, but do not provide data on supplier fair-trade certifications, audit frequency for suppliers, forced or child labor incidents in the supply chain, supply chain traceability, remediation speed for supplier violations, ethical clauses in supplier contracts, spend on high-risk materials, or supplier diversity spend.
1
Honest & Fair Business
0
No evidence available to assess Aptevo Therapeutics Inc. on Honest & Fair Business.
Kind to Animals
-40
The company's animal testing policy "exploits animals for product testing," indicating a policy that permits routine animal testing.
1
Preclinical data for product candidates like APVO436, ROR1 Bispecific, and APVO425 further confirm the use of animal models in their research and development.
2
No War, No Weapons
0
Aptevo Therapeutics Inc. is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, with a pipeline of product candidates targeting various types of cancer.
1
The company's core business involves medical treatments and does not include any defense or arms-related activities, dual-use technologies, or military applications. While a Code of Conduct exists, it does not provide specific details on ethical red lines related to weapons or compliance rates for such.
2
There is no evidence of revenue from arms contracts, investment in dual-use technologies, sales to embargoed regimes, or any involvement in peacebuilding or disarmament initiatives for Aptevo Therapeutics Inc. as the current entity. Information regarding military-grade devices and defense contracts in one article pertains to Emergent BioSolutions prior to the spin-off of Aptevo Therapeutics, and there is no evidence these activities or revenues transferred to Aptevo Therapeutics Inc. post-spin-off.
3
Planet-Friendly Business
-30
Aptevo Therapeutics Inc. achieved a waste recycling rate of 43% in 2023, with a target to reach 60% by 2027.
1
The company maintained a strong record of compliance with FDA regulations in 2024, reporting zero instances of non-compliance.
2
Respect for Cultures & Communities
0
No specific data or quantitative information regarding Aptevo Therapeutics Inc.'s performance on 'Respect for Cultures & Communities' KPIs is available in the provided articles.
1
The articles explicitly state that sustainability data is unavailable, and there are significant data gaps regarding the company's social responsibility and community impact, including cultural sensitivity, community engagement, and FPIC processes.
2
Safe & Smart Tech
0
Aptevo Therapeutics' privacy policy outlines user rights, including access, correction, deletion, and consent withdrawal, referencing GDPR and CCPA.
1
The policy also states that data retention is based on need and legal requirements, and discusses retention periods.
2
The company acknowledges being subject to comprehensive regulation by federal and state governments, including patient privacy regulations, and its policy explicitly mentions compliance with GDPR and other relevant regulations.
3
Zero Waste & Sustainable Products
0
No information related to 'Zero Waste & Sustainable Products' or any of the specific KPIs was found in the provided articles.
1
The articles focus on the company's biotechnology business, cancer treatment pipeline, corporate information, and financial news.
2